Numinus Wellness Revenue Jumps 29% as Trump Signs Psychedelic Research Order

Key Facts

1Numinus Wellness reported Q4 2025 revenue of $2.3 million, a 29% increase over the previous quarter.

2President Donald Trump signed an executive order to accelerate review of psychedelic-based treatments and committed $50 million in federal support.

Amid a shifting federal landscape for healthcare innovation, Numinus Wellness has reported financial results that signal a significant expansion in its operational reach. According to reports, the company achieved revenue of $2.3 million in the fourth quarter of 2025, marking a 29% increase over the previous quarter. This growth highlights the company's momentum as it navigates the evolving market for alternative therapeutic solutions.

This financial performance coincided with a major regulatory catalyst, as President Donald Trump signed an executive order to accelerate the review process for psychedelic-based treatments. The order commits $50 million in federal support for government programs, creating a highly favorable environment for the company's core business model. However, despite the revenue surge, data indicates the company's cash position remains tight at $0.5 million, necessitating careful liquidity management.

Looking ahead, investors are monitoring how the company will leverage these new regulatory tailwinds to improve gross profit margins. While current price levels for the instrument are unavailable as of August 28, 2026, broader economic indicators remain a key focus. Specifically, the Core PCE Price Index remained steady at 3.3% annually as of August 26, 2026, a metric that will influence Federal Reserve policy and the subsequent financing environment for growth-stage healthcare firms.